NFE2L2 and neoplasm: Interestingly, a study by DeBlasi et al. using the KrasG12D/+; p53fl/fl (KP) lung adenocarcinoma model found that the addition of NRF2 activation via Keap1R554Q/R554Q or Nrf2D29H/+ supported tumor initiation and progression of lesions into early stage (I and II) cancers but also identified a notable decrease in the burden of grade 3 and 4 tumors [22].